3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Dermatologic
1
Conditions
Melanoma
4
Sarcoma
1
Neoplasm Metastasis
1
Interventions
Cyclophosphamide
16
pembrolizumab
14
Radiosurgery
7
Nivolumab
5
Celecoxib
5
poly ICLC
4
Radiation
4
Injections
4
Radiotherapy
3
Melphalan
3
Ipilimumab
3
Filgrastim
3
Etoposide
3
Docetaxel
3
Cryosurgery
3
Blood Specimen Collection
3
Biopsy
3
130-nm albumin-bound paclitaxel
3
trastuzumab deruxtecan
2
tislelizumab
2
talimogene laherparepvec
2
spartalizumab
2
fludarabine phosphate
2
fludarabine
2
durvalumab
2
cemiplimab
2
atezolizumab
2
aldesleukin
2
Transurethral Resection of Prostate
2
Therapeutics
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Sarcoma
×
IMM-101
×
Dermatologic
×
Clear all
NCT03009058
2024-11-25
MODULATE
Immodulon Therapeutics Ltd
Phase 1/2
Terminated
2 enrolled
7 charts